Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Universidade Federal do Rio de Janeiro
With
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
The simvastatin can target the liver enhancing nitric oxide intra-hepatic and lowering resistance that may be responsible for most of cirrhosis complications. Indeed, the potential use of this drug may ameliorate the HVPG and azygos flow. Portal hypertension is responsible for most of the cases of death in cirrhosis. The esophageal varices, ascites and hepatorenal syndrome are the most harmful consequences of cirrhosis that should be prevented. In that way, simvastatin appears as a promising therapy.The study will include two groups of patients using aleatory randomization and one group will receive simvastatin while the other will receive placebo blindly. At the start and at the end of the study the patients will be submitted to HVPG measurement and azygous vein flow measure.
The endpoints will be the normalization of HVPG or lower significantly(20% or more.
The patients will be followed for 6 months after the end of the study.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Portal hypertension: esophageal varices, ascites, splenomegaly or hepatorenal syndrome.
You may not be if
Child-Pugh C decompensated or encephalopathy
Malignancy except basocellular cancer
Hepatocarcinoma
Anti-viral therapy
HIV
Prevention of digestive hemorrhage with band ligation or sclerotherapy for the last 6 months